source
- Epicrispr raises $90M to rewrite treatment of rare muscle diseaseEpicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an e…Fierce Biotech · 12h ago↗ source
- Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drugSentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.Fierce Biotech · 12h ago↗ source
- STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?Biotech companies don’t hide or obfuscate strong data.